The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
The restructured biotech’s new lead project enters phase 1.
The company will imminently start its third pivotal trial of PF-08634404.
The company ditches lorigerlimab in prostate cancer.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
But the Day One deal is still 29% below where the shares stood at the start of this year.
The response rate jumps to 30% with higher doses of IMA402.
